REVENUES OF TOP BIOPHARMACEUTICAL COMPANIES - 2022
1 CHF = 1.01 USD, 1 GBP = 1.16USD; 1EUR= 0.99 USD; 1DKK = 0.13 USD; 1 JPY = 0.0075 USD
Merck revenues include only pharmaceuticals (excluding animal health)
CLICK HERE TO CHECK TOP PHARMACEUTICALS BY REVENUES IN 2023
Pfizer reported revenues of $25.7 billion in the first quarter of 2022, reflecting operational growth of 82%. The revenues from the vaccines segment were $14.94 billion, the hospital segment was $3.19 billion, the oncology segment was $2.97 billion, and immunology was $820 million.
The revenue drivers of the company were Comirnaty ($13.23 billion), Prevnar family ($1.57 billion), Paxlovid ($1.47 billion), Eliquis ($ 1.79 billion), and Ibrance ($1.24 billion).
Pfizer reported revenues of $27.7 billion in the second quarter of 2022. Paxlovid and Comirnaty primarily drove the revenues.
The total revenues in the first half of 2022 were $53.4 billion. The vaccine segment contributed $25.4 billion, the hospital products segment (including Paxlovid) contributed $12.9 billion,
In the first half of 2022, Comirnaty revenues were $22.07 billion, Paxlovid was $9.6 billion, Ibrance was 2.5 billion, and Eliquis was $3.5 billion. Eliquis revenues increased by 13%, but Ibrance revenues dropped by 4%, and Xeljanz revenues reduced by 29%.
Also read: NICE Assessment Outcomes
Pfizer announced the revenues of the third quarter, reporting revenues of $22.6 billion, revenues declined by 2% versus last year.
In the first nine months, the revenues were $76 billion. The revenues from Comirnaty were $26.5 billion, Paxlovid was $17 billion, Eliquis was $5 billion, Prevanar family was $4.6 billion, Ibrance was $3.8 billion, and Xeljanz was $1.3 billion.